The COBIOPHAD project is a large-scale project consisting of 10 partners from 7 European countries, including research institutions, manufacturers and hospitals.

The main objective of COBIOPHAD is the development of an integrated biophotonic device based on compact disc technology to address allergy to beta-lactam antibiotics (penicillin, amoxicillin and cephalosporins), which is the most prevalent drug allergy in Europe. The project targets the development of a highly sensitive, selective, and multiplexed diagnostic device to provide a quick and inexpensive in vitro test. Using this test, the consortium aims to improve the appropriateness of antibiotic prescriptions thus obviating the need for antibiotic avoidance in case of false allergies. This will contribute to the sustainability of healthcare systems and improve the health status and quality of life of millions of European citizens suffering BLC allergies.

Supported by the EC (grant # 688448) and the Photonics public private partnership [PPP], the COBIOPHAD consortium aims to integrate multiple key enabling technologies [KETs] including use of advanced materials, opto-electronics, and bio-analytical tools along with cutting-edge manufacturing and cloud-based data networking systems.